Our research services operating group provides high-quality support services worldwide.
Tackle your biggest rederivation hurdles with help from our experienced project managersStream the webinar
Envigo offers the Wistar Institute Melanoma (WM) PDX model collection established from targeted therapy relapsed melanoma patients, spanning BRAF inhibitors, BRAK/MEK inhibitors, immune checkpoint inhibitors and targeted therapy and immunotherapy (TT/IT) combinations.
Read about testing second-line personalized medicine combination therapies, based on genomic and proteomic data, in patient-derived xenograft (PDX) models in Clinical Cancer Research by Krepler et al.
Xiao et al. (2019). A Melanoma Patient-Derived Xenograft Model. Journal of visualized experiments : JoVE, (147), 10.3791/59508. https://doi.org/10.3791/59508
Copyright © Envigo